

Holly Fernandez Lynch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1347757/publications.pdf>

Version: 2024-02-01

156
papers

1,392
citations

471509

17
h-index

414414

32
g-index

173
all docs

173
docs citations

173
times ranked

1717
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Social Media as a Research Recruitment Tool: Ethical Issues and Recommendations. American Journal of Bioethics, 2017, 17, 3-14.	0.9	306
2	A Framework for Ethical Payment to Research Participants. New England Journal of Medicine, 2018, 378, 766-771.	27.0	111
3	Ethics of controlled human infection to address COVID-19. Science, 2020, 368, 832-834.	12.6	95
4	Designing development programs for non-traditional antibacterial agents. Nature Communications, 2019, 10, 3416.	12.8	46
5	Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward. Yale Journal of Health Policy, Law, and Ethics, 2017, 17, 61-141.	1.5	42
6	Federal Right-to-Try Legislation " Threatening the FDA's Public Health Mission. New England Journal of Medicine, 2018, 378, 695-697.	27.0	39
7	When clinical trials compete: prioritising study recruitment. Journal of Medical Ethics, 2017, 43, 803-809.	1.8	37
8	Association Between Financial Incentives and Participant Deception About Study Eligibility. JAMA Network Open, 2019, 2, e187355.	5.9	35
9	Of Parachutes and Participant Protection: Moving Beyond Quality to Advance Effective Research Ethics Oversight. Journal of Empirical Research on Human Research Ethics, 2019, 14, 190-196.	1.3	27
10	Promoting Ethical Payment in Human Infection Challenge Studies. American Journal of Bioethics, 2021, 21, 11-31.	0.9	25
11	Differential payment to research participants in the same study: an ethical analysis. Journal of Medical Ethics, 2019, 45, 318-322.	1.8	24
12	Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization. American Journal of Bioethics, 2020, 20, 4-17.	0.9	23
13	Promoting Patient Interests in Implementing the Federal Right to Try Act. JAMA - Journal of the American Medical Association, 2018, 320, 869.	7.4	22
14	Informed Consent and the Role of the Treating Physician. New England Journal of Medicine, 2018, 378, 2433-2438.	27.0	20
15	Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?. American Journal of Bioethics, 2021, 21, 4-19.	0.9	20
16	Medical Malpractice and Black-Box Medicine. , 0, , 295-306.		18
17	Regulatory flexibility for COVID-19 research. Journal of Law and the Biosciences, 2020, 7, Isaa057.	1.6	18
18	Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways. Journal of Law, Medicine and Ethics, 2020, 48, 365-372.	0.9	18

#	ARTICLE	IF	CITATIONS
19	FDA Drug Approval and the Ethics of Desperation. JAMA Internal Medicine, 2021, 181, 1555.	5.1	18
20	Paying Research Participants: The Outsized Influence of "Undue Influence". IRB: Ethics & Human Research, 2017, 39, 1-9.	0.8	18
21	Revised "Common Rule"™ Shapes Protections For Research Participants. Health Affairs, 2017, 36, 784-788.	5.2	17
22	Addressing Financial Barriers to Enrollment in Clinical Trials. JAMA Oncology, 2018, 4, 913.	7.1	16
23	Patient-Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. IRB: Ethics & Human Research, 2018, 40, 7-17.	0.8	15
24	The rights and wrongs of intentional exposure research: contextualising the Guatemala STD inoculation study. Journal of Medical Ethics, 2012, 38, 513-515.	1.8	14
25	Implementing Regulatory Broad Consent Under the Revised Common Rule: Clarifying Key Points and the Need for Evidence. Journal of Law, Medicine and Ethics, 2019, 47, 213-231.	0.9	14
26	Is There a Duty to Share Healthcare Data?. , 0, , 209-222.		13
27	Oversight of Patient-Centered Outcomes Research: Recommendations From a Delphi Panel. Annals of Internal Medicine, 2018, 169, 559.	3.9	13
28	An ethics framework for consolidating and prioritizing COVID-19 clinical trials. Clinical Trials, 2021, 18, 226-233.	1.6	13
29	Discrimination at the Doctor's Office. New England Journal of Medicine, 2013, 368, 1668-1670.	27.0	12
30	Filthy Lucre or Fitting Offer? Understanding Worries About Payments to Research Participants. American Journal of Bioethics, 2019, 19, 1-4.	0.9	12
31	"We measure what we can measure" Struggles in defining and evaluating institutional review board quality. Social Science and Medicine, 2022, 292, 114614.	3.8	12
32	Making the case for completion bonuses in clinical trials. Clinical Trials, 2019, 16, 176-182.	1.6	11
33	Evaluating the Quality of Research Ethics Review and Oversight: A Systematic Analysis of Quality Assessment Instruments. AJOB Empirical Bioethics, 2020, 11, 208-222.	1.6	11
34	Challenges in confirming drug effectiveness after early approval. Science, 2021, 374, 1205-1207.	12.6	11
35	Protecting clinical trial participants and study integrity in the age of social media. Cancer, 2018, 124, 4610-4617.	4.1	10
36	The right to withdraw from controlled human infection studies: Justifications and avoidance. Bioethics, 2020, 34, 833-848.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Waivers and Alterations of Research Informed Consent During the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2021, 174, 415-416.	3.9	10
38	Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. <i>Journal of Medical Ethics</i> , 2016, 42, 229-234.	1.8	9
39	Big Data and Intellectual Property Rights in the Health and Life Sciences. , 0, , 311-323.		9
40	Institutional Review Board Quality, Private Equity, and Promoting Ethical Human Subjects Research. <i>Annals of Internal Medicine</i> , 2020, 173, 558-562.	3.9	8
41	Institutional Review Board Use of Outside Experts: A National Survey. <i>AJOB Empirical Bioethics</i> , 2022, 13, 251-262.	1.6	8
42	Participant Protection in Phase 1 Pediatric Cancer Trials. <i>JAMA Pediatrics</i> , 2019, 173, 8.	6.2	7
43	Paying Clinical Trial Participants: Legal Risks and Mitigation Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 532-537.	1.6	7
44	Right to Try Requests and Oncologistsâ€™ Gatekeeping Obligations. <i>Journal of Clinical Oncology</i> , 2020, 38, 111-114.	1.6	7
45	Paying Participants in COVID-19 Trials. <i>Journal of Infectious Diseases</i> , 2020, 222, 356-361.	4.0	7
46	The limits of acceptable political influence over the FDA. <i>Nature Medicine</i> , 2021, 27, 188-190.	30.7	7
47	A snapshot of U.S. IRB review of COVID-19 research in the early pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e205.	0.6	7
48	Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab. <i>Drugs and Aging</i> , 2022, 39, 389-400.	2.7	7
49	Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1553.	7.4	6
50	Academic Advocacy. <i>Academic Medicine</i> , 2020, 95, 44-51.	1.6	6
51	IRB Oversight of Patient-Centered Outcomes Research: A National Survey of IRB Chairpersons. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 421-431.	1.3	6
52	Patient-Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. <i>IRB: Ethics & Human Research</i> , 2018, 40, 7-17.	0.8	6
53	Nonexceptionalism, Research Risks, and Social Media: Response to Open Peer Commentaries on â€œUsing Social Media as a Research Recruitment Tool: Ethical Issues and Recommendationsâ€. <i>American Journal of Bioethics</i> , 2017, 17, W1-W3.	0.9	5
54	Reopening schools safely in the face of COVID-19: Can cluster randomized trials help?. <i>Clinical Trials</i> , 2021, 18, 371-376.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Streamlining Review by Accepting Equivalence. <i>American Journal of Bioethics</i> , 2014, 14, 11-13.	0.9	4
56	Truth in Advertising: Disclosure of Participant Payment in Research Recruitment Materials. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 268-274.	1.6	4
57	Big Data's New Discrimination Threats. , 0, , 85-97.		4
58	Avoiding Overregulation in the Medical Internet of Things. , 0, , 129-141.		4
59	Mountains and Molehills When Using Social Media as a Research Support Tool. <i>American Journal of Bioethics</i> , 2019, 19, 64-66.	0.9	4
60	Compensating for research risk: permissible but not obligatory. <i>Journal of Medical Ethics</i> , 2020, 46, 827-828.	1.8	4
61	Ethical Payment to Participants in Human Infection Challenge Studies, with a Focus on SARS-CoV-2: Report and Recommendations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
62	Reaping the Bounty of Publicly Available Clinical Trial Consent Forms. <i>IRB: Ethics & Human Research</i> , 2017, 39, 10-15.	0.8	4
63	How Do Accredited Organizations Evaluate the Quality and Effectiveness of Their Human Research Protection Programs?. <i>AJOB Empirical Bioethics</i> , 2023, 14, 23-37.	1.6	4
64	Contraceptive Coverage and the Balance Between Conscience and Access. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2179.	7.4	3
65	How Much May Religious Accommodations Burden Others?. , 0, , 215-229.		3
66	A Common Law Duty to Disclose Conscience-Based Limitations on Medical Practice. , 2017, , 187-197.		3
67	Correlation versus Causation in Health-Related Big Data Analysis. , 0, , 42-55.		3
68	Who's Left Out of Big Data?. , 0, , 98-111.		3
69	Biospecimens, Research Consent, and Distinguishing Cell Line Research. <i>JAMA Oncology</i> , 2019, 5, 406.	7.1	3
70	Minimal or reasonable? Considering the ethical threshold for research risks to nonconsenting bystanders and implications for nonconsenting participants. <i>Bioethics</i> , 2020, 34, 923-932.	1.4	3
71	Ethical Inclusion of Health Care Workers in Covid-19 Research. <i>Ethics & Human Research</i> , 2021, 43, 19-27.	0.9	3
72	Religious Outliers. , 2017, , 173-186.		2

#	ARTICLE	IF	CITATIONS
73	Religion and Reproductive Technology. , 2017, , 360-371.		2
74	Mutual Obligations in Research and Withholding Payment From Deceptive Participants. American Journal of Bioethics, 2018, 18, 85-87.	0.9	2
75	Big Data's Epistemology and Its Implications for Precision Medicine and Privacy. , 0, , 30-41.		2
76	Big Data and Regulatory Arbitrage in Healthcare. , 0, , 56-68.		2
77	Thought-Leader Perspectives on Risks in Precision Medicine Research. , 0, , 161-174.		2
78	Big Data, HIPAA, and the Common Rule. , 0, , 251-264.		2
79	The role of community engagement in addressing bystander risks in research: The case of a Zika virus controlled human infection study. Bioethics, 2020, 34, 883-892.	1.4	2
80	Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research. Annals of Internal Medicine, 2021, 174, 256-257.	3.9	2
81	Give them what they want? The permissibility of pediatric placebo-controlled trials under the best pharmaceuticals for children act. Health System Leader, 2007, 16, 79-138, table of contents.	0.4	2
82	Institutions as an ethical locus of research prioritisation. Journal of Medical Ethics, 2017, 43, 816-818.	1.8	1
83	A Functional Approach to Assessing Consent for Biospecimen Research. American Journal of Bioethics, 2017, 17, 20-23.	0.9	1
84	Brain Death Rejected. , 2017, , 293-305.		1
85	Reclaiming Biopolitics: Religion and Psychiatry in the Sexual Orientation Change Therapy Cases and the Establishment Clause Defense. , 0, , 276-288.		1
86	On Scarcity and the Value of Clinical Trials. American Journal of Bioethics, 2018, 18, 71-73.	0.9	1
87	Big Data and Individual Autonomy in a Crowd. , 0, , 19-29.		1
88	The Future of Pharmacovigilance. , 0, , 73-84.		1
89	The Common Rule and Research with Data, Big and Small. , 0, , 237-250.		1
90	Big Data and Human Medical Judgment. , 0, , 283-294.		1

#	ARTICLE	IF	CITATIONS
91	The Pathologies of Data-Generating Patents. , 0, , 324-336.		1
92	The European Medicines Agency's Approach to Transparency. , 2019, , 210-226.		1
93	Smashing into Windows. , 2019, , 17-29.		1
94	Is Pharmaceutical Price Transparency an Effective Means to Reduce High Prices and Wide Variations?. , 2019, , 132-152.		1
95	Using Disclosure to Regulate PBMs. , 2019, , 343-356.		1
96	Price Transparency. , 2019, , 153-164.		1
97	Offering Payment in Clinical Research: Enrolling Individuals With or at Risk for Opioid Use Disorder. Journal of Empirical Research on Human Research Ethics, 2020, 15, 163-174.	1.3	1
98	Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies. Hastings Center Report, 2022, 52, 51-58.	1.0	1
99	Not Your Father's Religious Exemptions: The Contraceptive- Coverage Litigation and the Rights of Others. , 0, , 60-74.		0
100	Unpacking the Relationship Between Conscience and Access. , 0, , 242-258.		0
101	Accommodating Miracles: Medical Futility and Religious Free Exercise. , 0, , 306-318.		0
102	RELIGION AND REPRODUCTIVE HEALTH CARE: INTRODUCTION. , 0, , 345-347.		0
103	Contracting Religion. , 0, , 113-124.		0
104	Introduction: Law, Religion, and Health in the United States. , 0, , 1-18.		0
105	LAW, RELIGION, AND HEALTH CARE INSTITUTIONS: INTRODUCTION. , 0, , 87-89.		0
106	Mission Integrity Matters: Balancing Catholic Health Care Values and Public Mandates. , 0, , 125-138.		0
107	Bosses in the Bedroom: Religious Employers and the Future of Employer- Sponsored Health Care. , 0, , 154-168.		0
108	PROFESSIONAL RESPONSIBILITIES, RELIGION, AND HEALTH CARE: INTRODUCTION. , 0, , 169-172.		0

#	ARTICLE	IF	CITATIONS
109	Religious Convictions About Homosexuality and the Training of Counseling Professionals: How Should We Treat Religious- Based Opposition to Counseling About Same- Sex Relationships?. , 0, , 263-275.		0
110	Religion and the Unborn Under the First Amendment. , 0, , 372-382.		0
111	Race, Religion, and Masculinity: The HIV Double Bind. , 0, , 387-398.		0
112	Religious Liberty, Health Care, and the Culture Wars. , 0, , 21-33.		0
113	Religious Exemptions to the Individual Mandate: Health Care Sharing Ministries and the Affordable Care Act. , 0, , 143-153.		0
114	A Corporation's Exercise of Religion: A Practitioner's Experience. , 0, , 90-102.		0
115	â€œA Patchwork Array of Theocratic Fiefdoms?â€•RFRA Claims Against the ACA's Contraception Mandate as Examples of the New Feudalism. , 0, , 230-241.		0
116	The HHS Mandate Litigation and Religious Health Care Providers. , 0, , 47-59.		0
117	Recent Applications of the Supreme Court's Hands- Off Approach to Religious Doctrine: From Hosanna- Tabor and Holt to Hobby Lobby and Zubik. , 0, , 75-86.		0
118	A CASE STUDY â€œ RELIGIOUS BELIEFS AND THE HEALTH OF THE LGBT COMMUNITY: INTRODUCTION. , 0, , 259-262.		0
119	When Religion Pollutes: How Should Law Respond When Religious Practice Threatens Public Health?. , 0, , 411-422.		0
120	From Smith to Hobby Lobby : The Transformation of the Religious Freedom Restoration Act. , 0, , 34-46.		0
121	The Natural Person as the Limiting Principle for Conscience: Can a Corporation Have a Conscience If It Doesn't Have an Intellect and Will?. , 0, , 103-112.		0
122	Conscientious Objection, Complicity, and Accommodation. , 0, , 203-214.		0
123	Putting the Insanity Defense on Trial: Understanding Criminality in the Context of Religion and Mental Illness. , 0, , 319-331.		0
124	Religion as a Controlling Interference in Medical Decision Making by Minors. , 0, , 332-344.		0
125	Regulating Reasons: Governmental Regulation of Private Deliberation in Reproductive Decision Making. , 0, , 348-359.		0
126	RELIGION, LAW, AND PUBLIC HEALTH: INTRODUCTION. , 0, , 383-386.		0

#	ARTICLE	IF	CITATIONS
127	The Intersection of Law, Religion, and Infectious Disease in the Handling and Disposition of Human Remains. , 0, , 399-410.		0
128	Potential Roadblocks in Healthcare Big Data Collection. , 0, , 112-124.		0
129	Data Policy for Internet of Things Healthcare Devices. , 0, , 142-156.		0
130	From Individual to Group Privacy in Biomedical Big Data. , 0, , 175-192.		0
131	Big Data and Informed Consent. , 0, , 193-204.		0
132	Societal Lapses in Protecting Individual Privacy, the Common Rule, and Big Data Health Research. , 0, , 223-236.		0
133	Data Sharing that Enables Postapproval Drug and Device Research and Protects Patient Privacy. , 0, , 269-282.		0
134	Nontransparency in Electronic Health Record Systems. , 2019, , 273-285.		0
135	The Interplay of Privacy and Transparency in Health Care. , 2019, , 30-43.		0
136	Transparency Trade-offs. , 2019, , 44-57.		0
137	Slightly Hazy. , 2019, , 58-68.		0
138	Transparency versus Informed Consent. , 2019, , 75-87.		0
139	Transparency and Financial Conflicts. , 2019, , 88-102.		0
140	Making Religion Transparent. , 2019, , 103-114.		0
141	Transparency on Prescription Drug Research Expenditures. , 2019, , 121-131.		0
142	Solving Surprise Medical Bills. , 2019, , 165-178.		0
143	Increasing the Transparency of FDA Review to Enhance the Innovation Process. , 2019, , 185-195.		0
144	Transparency and Clinical Trial Data Sharing. , 2019, , 196-209.		0

#	ARTICLE	IF	CITATIONS
145	Introduction to Part V. , 2019, , 229-232.		0
146	The Role of Transparency in Promoting Healthy Behaviors. , 2019, , 233-243.		0
147	The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259.		0
148	Personal Health Records as a Tool for Transparency in Health Care. , 2019, , 260-272.		0
149	Transparency Challenges in Reproductive Health Care. , 2019, , 286-296.		0
150	Introduction to Part VI. , 2019, , 299-300.		0
151	ERISA as a Barrier for State Health Care Transparency Efforts. , 2019, , 301-313.		0
152	Transparency and Data Sharing in Clinical Research and Big Pharma. , 2019, , 314-328.		0
153	Promoting IRB Transparency. , 2019, , 329-342.		0
154	Ethical Review and Methodologic Innovation in Phase 1 Cancer Trialsâ€™Reply. JAMA Pediatrics, 2019, 173, 609.	6.2	0
155	No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical Trials. American Journal of Bioethics, 2020, 20, W1-W4.	0.9	0
156	Plumbing the Depths of Ethical Payment for Research Participation. American Journal of Bioethics, 2021, 21, W8-W11.	0.9	0